Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck KGaA
Biotech
Merck KGaA drops evobrutinib in wake of double phase 3 fail
Only months ago, Merck KGaA was outlining hopes for a major commercialization push. Now the German pharma has dropped the BTK inhibitor completely.
James Waldron
Mar 7, 2024 9:54am
Merck KGaA paying $16M to join C4's protein degrader hunt
Mar 4, 2024 10:18am
2023's top 10 clinical trial flops
Jan 22, 2024 6:00am
Avenzo, Merck KGaA and AbbVie each ink new cancer deals
Jan 4, 2024 10:26am
It’s a wrap for Merck KGaA and Mersana’s 2014 ADC pact
Dec 22, 2023 10:37am
Merck KGaA's BTK drug flunks pivotal multiple sclerosis trials
Dec 6, 2023 4:30am